2. Academic Validation
  3. Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook

Phosphodiesterase 4 Inhibitor Therapies for Atopic Dermatitis: Progress and Outlook

  • Drugs. 2017 Sep;77(13):1389-1397. doi: 10.1007/s40265-017-0784-3.
Jusleen Ahluwalia 1 2,  Jeremy Udkoff 3 4,  Andrea Waldman 3 4,  Jenna Borok 3 4,  Lawrence F Eichenfield 3 4
Affiliations

Affiliations

  • 1 Department of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, 8010 Frost Street, Suite 602, San Diego, CA, 92123, USA. [email protected].
  • 2 Department of Pediatric and Adolescent Dermatology, San Diego School of Medicine, University of California, 9500 Gillman Drive, La Jolla, CA, 92093, USA. [email protected].
  • 3 Department of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, 8010 Frost Street, Suite 602, San Diego, CA, 92123, USA.
  • 4 Department of Pediatric and Adolescent Dermatology, San Diego School of Medicine, University of California, 9500 Gillman Drive, La Jolla, CA, 92093, USA.
PMID: 28681318 DOI: 10.1007/s40265-017-0784-3
Abstract

Phosphodiesterase 4 (PDE4) is a cyclic AMP degrading Enzyme in leukocytes. Several decades ago, increased PDE activity was demonstrated in patients with atopic dermatitis (AD). Currently, several PDE4 inhibitors in both topical and oral formulation have been developed to target the inflammatory cascade of AD. This review shows the pathogenic rationale behind these inhibitors, and discusses multiple PDE4 inhibitors that are under evaluation or in the market. PDE4 inhibitors may be considered as favorable agents in the repertoire of current interventions for AD.

Figures
Products